NewsBenzingaUBS mantiene la recomendación de compra sobre Neurocrine Biosciences y reduce el precio objetivo a 214 dólares UBS mantiene la recomendación de compra sobre Neurocrine Biosciences y reduce el precio objetivo a 214 dólares Benzinga 2026.09.29 19:04 (GMT+0) Open on Benzinga Other news Rocket Lab Steps In Where SpaceX Just Walked Away This Analyst Says It's Time to Buy Royal Caribbean Stock. Here's Why. Stocks Settle Mixed as Bond Yields Rise Bloom Energy Is Up More Than 200% So Far This Year. What Comes Next for BE Stock. 'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana Moment Carnival Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana Moment
